Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

26.7%

12 terminated/withdrawn out of 45 trials

Success Rate

70.7%

-15.8% vs industry average

Late-Stage Pipeline

11%

5 trials in Phase 3/4

Results Transparency

52%

15 of 29 completed trials have results

Key Signals

3 recruiting15 with results10 terminated

Enrollment Performance

Analytics

Phase 1

26(59.1%)

Phase 2

11(25.0%)

Phase 3

5(11.4%)

N/A

2(4.5%)

44Total

Phase 1(26)

Phase 2(11)

Phase 3(5)

N/A(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (45)

Showing 20 of 45 trials

NCT04987203Phase 3Completed

Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma

Role: lead

NCT06053658Phase 2Recruiting

Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma

Role: collaborator

NCT06064877Phase 3Recruiting

A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma

Role: lead

NCT05865535Phase 1Recruiting

A Dose Escalation Study of AV-380 in Cancer Patients With Cachexia

Role: lead

NCT02627963Phase 3Completed

A Study to Compare Tivozanib Hydrochloride to Sorafenib in Participants With Refractory Advanced Renal Cell Carcinoma (RCC)

Role: lead

NCT03970616Phase 1Terminated

A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma

Role: lead

NCT04815551Phase 1Completed

A Phase 1 Study of AV-380 in Healthy Subjects

Role: lead

NCT01769885Not ApplicableWithdrawn

Tivozanib Before Surgery in Treating Patients With Localized Kidney Cancer

Role: collaborator

NCT03136627Phase 1Completed

Phase 1/2 Study of Tivozanib in Combination With Nivolumab in Subjects With RCC

Role: lead

NCT03316599Phase 1Completed

Study of Gemcitabine, Nab-paclitaxel, and Ficlatuzumab (AV-299) in Patients With Advanced Pancreatic Cancer

Role: collaborator

NCT01835223Phase 1Completed

Tivozanib in Treating Patients With Liver Cancer That Is Metastatic or Cannot Be Removed by Surgery

Role: collaborator

NCT01297244Phase 2Completed

A Biomarker Study of Tivozanib in Subjects With Advanced Renal Cell Carcinoma

Role: lead

NCT01745367Phase 2Terminated

Tivozanib in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer

Role: lead

NCT01673386Phase 2Terminated

A Subject Treatment Preference Study of Tivozanib Versus Sunitinib in Subjects With Metastatic RCC

Role: lead

NCT02318368Phase 2Terminated

A Phase 2, Study of Ficlatuzumab Plus Erlotinib vs. Placebo Plus Erlotinib in Subjects With Previously Untreated Metastatic, EGFR-mutated NSCLC and BDX004 Positive Label

Role: lead

NCT01076010Phase 3Completed

An Extension Treatment Protocol for Subjects Who Have Participated in a Study of Tivozanib Versus Sorafenib in Kidney Carcinoma (Protocol AV-951-09-301).

Role: lead

NCT00502307Phase 2Completed

A Study of Tivozanib (AV-951), an Oral VEGF Receptor Tyrosine Kinase Inhibitor, in the Treatment of Renal Cell Carcinoma

Role: lead

NCT01369433Not ApplicableTerminated

A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols

Role: lead

NCT04100330Phase 2Withdrawn

A Study of Ficlatuzumab With HiDAC and HiDAC Alone in Adults With Relapsed or Refractory Acute Myeloid Leukemia

Role: lead

NCT02109627Phase 1Terminated

Ficlatuzumab With High Dose Cytarabine in Relapsed and Refractory AML

Role: collaborator